Early trial tests diabetes drug for MS pain relief
NCT ID NCT07221799
Summary
This early-stage study is testing whether an extended-release version of the diabetes drug glibenclamide (glyburide) can safely help reduce nerve pain in people with multiple sclerosis. Ten participants will first take the drug for five days to check safety, then continue for three months to see if it eases their pain. The study uses a design where participants serve as their own comparison to measure pain relief effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROPATHIC PAIN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Maryland School of Medicine
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.